Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo Coronary Artery Bypass Surgery
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG
• Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination.
• Others
Locations
Other Locations
Japan
The University of Osaka Hospital
RECRUITING
Osaka
Contact Information
Primary
Sumito Okawa, Study Director
R-regenerative_medicine@rohto.co.jp
81-3-6832-6014
Backup
Toshiyuki Osawa
R-regenerative_medicine@rohto.co.jp
81-6-6447-8610
Time Frame
Start Date: 2026-04-28
Estimated Completion Date: 2029-03-31
Participants
Target number of participants: 50
Treatments
Experimental: Mesenchymal stem cell
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Rohto Pharmaceutical Co., Ltd.